DE60012751D1 - Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz - Google Patents

Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz

Info

Publication number
DE60012751D1
DE60012751D1 DE60012751T DE60012751T DE60012751D1 DE 60012751 D1 DE60012751 D1 DE 60012751D1 DE 60012751 T DE60012751 T DE 60012751T DE 60012751 T DE60012751 T DE 60012751T DE 60012751 D1 DE60012751 D1 DE 60012751D1
Authority
DE
Germany
Prior art keywords
neuropathic pain
receptor ligands
treating neuropathic
treating
phenylüacetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60012751T
Other languages
English (en)
Other versions
DE60012751T2 (de
Inventor
Nicholas Maughan Clayton
Susanne Denise Collins
Steven Michael Foord
Gerard Martin Paul Giblin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918745.2A external-priority patent/GB9918745D0/en
Priority claimed from GBGB9928437.4A external-priority patent/GB9928437D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60012751D1 publication Critical patent/DE60012751D1/de
Application granted granted Critical
Publication of DE60012751T2 publication Critical patent/DE60012751T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60012751T 1999-08-10 2000-08-08 Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz Expired - Lifetime DE60012751T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9918745 1999-08-10
GBGB9918745.2A GB9918745D0 (en) 1999-08-10 1999-08-10 Medical uses
GBGB9928437.4A GB9928437D0 (en) 1999-12-01 1999-12-01 Medical uses
GB9928437 1999-12-01
PCT/EP2000/007669 WO2001010426A2 (en) 1999-08-10 2000-08-08 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer

Publications (2)

Publication Number Publication Date
DE60012751D1 true DE60012751D1 (de) 2004-09-09
DE60012751T2 DE60012751T2 (de) 2005-01-20

Family

ID=26315833

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60012751T Expired - Lifetime DE60012751T2 (de) 1999-08-10 2000-08-08 Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz
DE60032524T Expired - Lifetime DE60032524T2 (de) 1999-08-10 2000-08-08 EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60032524T Expired - Lifetime DE60032524T2 (de) 1999-08-10 2000-08-08 EP4 Rezeptor Ligand und Verwendung gegen neuropathischen Schmerzen, Colon Krebs, HIV und Migräne

Country Status (8)

Country Link
US (1) US6861441B1 (de)
EP (2) EP1442744B1 (de)
JP (1) JP2003506404A (de)
AT (2) ATE272398T1 (de)
AU (1) AU6836200A (de)
DE (2) DE60012751T2 (de)
ES (2) ES2274378T3 (de)
WO (1) WO2001010426A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
ATE395058T1 (de) * 2000-03-24 2008-05-15 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
ATE371454T1 (de) * 2001-10-31 2007-09-15 Medical Res Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
US7547715B2 (en) 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
CA2563356A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
GB0602900D0 (en) * 2006-02-13 2006-03-22 Glaxo Group Ltd Novel Compounds
GB0615111D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel compounds
GB0616498D0 (en) * 2006-08-18 2006-09-27 Glaxo Group Ltd Novel compounds
GB0620619D0 (en) * 2006-10-17 2006-11-29 Glaxo Group Ltd Novel compounds
GB0623203D0 (en) * 2006-11-21 2007-01-03 Glaxo Group Ltd Novel compounds
CN101686985A (zh) * 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
GB0715463D0 (en) * 2007-08-08 2007-09-19 Glaxo Group Ltd Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
BRPI1014174B8 (pt) 2009-04-22 2021-05-25 Askat Inc uso de um composto selecionado a partir de 4-((1s)-1-{[5-cloro-2-(4-fluorofenóxi)benzoil]amino}etil)ácido benzóico, 4-[(1s)-1-({[5-cloro-2-(3-fluorofenóxi)piridin-3-il]carbonil}amino)etil]ácido benzóico e 3-[2-(4-{2-etil-4,6-dimetil-1h-imidazo[4,5-c]piridin-1-il}fenil)etil]-1-[(4-metilbenzeno)sulfonil]urea para tratamento de um câncer epitelial relacionado à pge2
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
JP2015522528A (ja) 2012-05-09 2015-08-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 慢性閉塞性肺疾患の予防または治療方法および医薬組成物
EP2913047B1 (de) 2012-10-29 2019-05-08 Cardio Incorporated Spezifisches therapeutikum für pulmonale erkrankungen
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
WO2015134792A1 (en) * 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574409A5 (en) * 1972-09-29 1976-04-15 Sandoz Ag Benzo(f)isoindoline derivs - with antidepressant and analgesic activity
IL62734A (en) * 1980-04-30 1985-10-31 Glaxo Group Ltd Aminocyclopentane alkenoic acids and esters,their preparation and pharmaceutical formulations
US4618683A (en) * 1982-06-01 1986-10-21 Abbott Laboratories Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives
NO872963L (no) * 1986-07-29 1988-02-01 Glaxo Group Ltd Isokinolinderivater.
EP0501579A1 (de) * 1991-02-28 1992-09-02 Merck Frosst Canada Inc. Naphthalinlactone als Inhibitoren der Leukotrien-Biosynthese
EP0520573A1 (de) * 1991-06-27 1992-12-30 Glaxo Inc. Derivate von cyclischen Imiden
EP0757681B1 (de) * 1994-04-29 2002-09-18 Takeda Chemical Industries, Ltd. KONDENSIERTE HETEROCYCLISCHE VERBINDUNG, DEREN HERSTELLUNG UND VERWENDUNG ALS GnRH ANTAGONISTEN
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors

Also Published As

Publication number Publication date
ATE272398T1 (de) 2004-08-15
US6861441B1 (en) 2005-03-01
WO2001010426A2 (en) 2001-02-15
WO2001010426A3 (en) 2001-12-20
EP1442744B1 (de) 2006-12-20
DE60032524D1 (de) 2007-02-01
ES2225199T3 (es) 2005-03-16
ATE348608T1 (de) 2007-01-15
EP1442744A2 (de) 2004-08-04
DE60032524T2 (de) 2007-07-05
DE60012751T2 (de) 2005-01-20
EP1442744A3 (de) 2005-04-06
ES2274378T3 (es) 2007-05-16
EP1202730B1 (de) 2004-08-04
EP1202730A2 (de) 2002-05-08
JP2003506404A (ja) 2003-02-18
AU6836200A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
FI935529A (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
NO20014925D0 (no) Farmasöytiske forbindelser
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
DK0807630T3 (da) Heterocykliske forbindelser
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ID24846A (id) Turunan-turunan bifenilamidina
DK0835868T3 (da) 2-aryl-3-aminoaryloxynaphthylforbindelser, mellemprodukter, sammensætninger og fremgangsmåder
ATE239741T1 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
ATE235450T1 (de) 2-indanmethanolderivate und ihre verwendung als riechstoffe
DE69533214D1 (de) 2,3-Dihydro-1H-isoindolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Hemmer der Serotoninwiederaufnahme
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ATE264840T1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
TH26544A (th) อนุพันธ์กรด -4 - อัลคิลไทโอ -ไพรมิดิน -5 - อิล อาซีติก
DE59905342D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
RO116896B1 (ro) Derivaţi pseudocarbaciclinici şi procedeu pentru prepararea acestora

Legal Events

Date Code Title Description
8364 No opposition during term of opposition